Jun 15, 2022 / 04:20PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Okay. Good morning, everybody. This is the place to be, obviously, with Pfizer and now with Bristol. Thank you for staying with us during our Goldman Sachs Healthcare Conference. Excuse me for that. My name is Chris Shibutani. I'm a member of the research team, cover pharmaceuticals and biotechnology.
We are thrilled to have Bristol-Myers join us as well. When we launched our coverage there, by recommendation and the stock has been amongst the most resilient in this environment. Lot of exciting fundamentals. Very pleased that we could have with us a point person who I think can really give voice to many of the things that will move the needle here, and it's an exciting time for Bristol, Adam Lenkowsky. Adam, you are, I think by title, General Manager of U.S. Commercial?
Adam Lenkowsky - Bristol-Myers Squibb Company - Head of U.S. Oncology
Correct.
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Bristol-Myers Squibb Co at Goldman Sachs Global Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers